Drug intelligence / Profile preview

1,8-dihydroxy-4-nitro-xanthen-9-one

Development stage: Unknown
Modality: Classical Binding Small Molecules → Small Molecules

Overview

1,8-dihydroxy-4-nitro-xanthen-9-one is a synthetic small molecule belonging to the xanthone class. It is characterized by a xanthene core substituted with hydroxy groups at positions 1 and 8 and a nitro group at position 4. The compound acts as an inhibitor of casein kinase II subunit alpha (CSNK2A1), a serine/threonine protein kinase involved in various cellular processes including cell cycle control and apoptosis. This molecule has been studied experimentally for its protein kinase inhibitory activity but has not been approved for clinical use or advanced beyond preclinical research[2][1][3].

Other names: 1,8-dihydroxy-4-nitroxanthen-9-one1,8-dihydroxy-4-nitro-9H-xanthen-9-one

Targets

CK2 (Casein kinase II subunit alpha)

Beyond the preview

Go deeper on 1,8-dihydroxy-4-nitro-xanthen-9-one.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1,8-dihydroxy-4-nitro-xanthen-9-one.

Explore the full profile